ClinicalTrials.gg
CompletedNCT00756444Updated Nov 15, 2018Results posted

A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck

A Phase 2 interventional study of Panitumumab and Cisplatin in Squamous Cell Carcinoma of Head and Neck, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-15.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing panitumumab in Squamous Cell Carcinoma of Head and Neck — 4 open to participants now, 4 under way, none of them phase 3. Panitumumab · Squamous Cell Carcinoma of Head and Neck.

Enrollment
3rd of 10
67 · median 32
Started
2008
with 1 other
Phase 2
2 of 10
none open now
Registered
2nd of 10
by date
Lead sponsor
1 of 10
Amgen

Among the 10 studies testing panitumumab in Squamous Cell Carcinoma of Head and Neck, this one is the 3rd largest by enrollment, is one of 2 that started in 2008, is one of 2 in phase 2, and was the 2nd registered.

Squamous Cell Carcinoma of Head and Neck

2,020 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

4 of the 10 studies testing panitumumab in Squamous Cell Carcinoma of Head and Neck are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About panitumumab

Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing panitumumab in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

Study 20080008 was a PK sub-study to study 20050251[Japan 20050251A]. This PK protocol was amended 20-March-2009 and is now a Phase 2 stand alone study. There are no sites participating in the U.S.

This study is designed to estimate the effect of panitumumab on the PK of cisplatin and 5-FU in subjects receiving cisplatin and 5-FU with or without panitumumab.

To maximize any potential effect of panitumumab on the PK of cisplatin and 5-FU, the collection of PK samples of cisplatin and 5-FU will be taken during cycle 2 of the study, the point at which the PK of panitumumab is expected to be at steady-state after a dose of 9 mg/kg given every 3 weeks.

Read the detailed description

Study Phase: 2 Indication: Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck Primary Objective: To estimate the effect of administration of 9 mg/kg Q3W of panitumumab on the area under the curve (AUC) of total plasma cisplatin-derived platinum levels and the average concentration at steady state (Css) of 5-fluorouracil (5-FU) in subjects who are receiving cisplatin and 5-FU.

Secondary Objective(s): To estimate the effect of administration of 9 mg/kg Q3W of panitumumab on the maximum concentration (Cmax) of total plasma cisplatin-derived platinum levels, AUC and Cmax of free plasma cisplatin-derived platinum in subjects who are receiving cisplatin and 5-FU.

Hypotheses: This is an estimation sub-study rather than formal hypothesis testing, the following will be estimated:

  1. The effect of administration of 9 mg/kg Q3W of panitumumab at steady state on the pharmacokinetics of cisplatin will be estimated based on the ratio for AUC with:without panitumumab of total plasma cisplatin-derived platinum levels. Total plasma cisplatin-derived platinum levels will be the focus since it has been shown in the literature that there are correlations between total plasma cisplatin-derived platinum levels and nephrotoxicity and tumor response (Desoize et al, 1991).
  2. The effect of administration of 9 mg/kg Q3W of panitumumab at steady state on the pharmacokinetics of 5-FU assessed based on the average concentration at steady state (Css) of 5-FU.

Study Design: Study 20080008 is a PK study.

This study is designed to estimate the effect of panitumumab on the PK of cisplatin and 5-FU in subjects receiving cisplatin and 5-FU with or without panitumumab.

To maximize any potential effect of panitumumab on the PK of cisplatin and 5-FU, the collection of PK samples of cisplatin and 5-FU will be taken during cycle 2 of the study, the point at which the PK of panitumumab is expected to be at steady-state after a dose of 9 mg/kg given every 3 weeks.

Primary and Secondary Endpoints: The primary endpoints for this study are the ratio of geometric means (with:without panitumumab) for AUC of total plasma cisplatin-derived platinum and average concentration at steady sate (Css) of 5-FU measured at cycle 2 at which time panitumumab levels are anticipated to be at steady state. Secondary endpoints are the ratio of geometric means (with:without panitumumab) for 1) Cmax of total plasma cisplatin-derived platinum and 2) Cmax and AUC of free plasma cisplatin-derived platinum measured at cycle 2.

Sample Size: Approximately 45 subjects will participate in Study 20080008. At least fifteen evaluable subjects (defined as providing sufficient PK samples to permit calculation of AUC for total plasma cisplatin-derived platinum and average concentration at steady state for 5-FU in cycle 2) per arm will be required. Additional subjects will be sequentially included until at least fifteen evaluable subjects per arm are achieved. It is therefore estimated that approximately 45 subjects will need to participate in the study to obtain 30 evauable subjects.

03

Conditions studied

  • Squamous Cell Carcinoma of Head and Neck

Keywords

  • PK Study, Metastatic Recurrent
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed squamous cell carcinoma of the head and neck (SCCHN) or its variants (eg, basaloid squamous cell carcinoma and adenosquamous cell carcinoma) of the oral cavity, oropharynx, hypopharynx, or larynx
  • Diagnosis of disease and/or recurrent disease following locoregional therapy and determined to be incurable by surgery or radiotherapy
  • Subjects who have received radiation as primary therapy are eligible if locoregional recurrence is in the field of radiation and has occurred ≥6 months after the completion of radiation therapy. Subjects whose locoregional recurrence is solely outside the field of radiation are eligible if the recurrence has occurred ≥ 3 months after the completion of radiation therapy.
  • Measurable or non . Target lesions must not be chosen from a previously irradiated field unless there has been radiographically and/or pathologically documented tumor progression in that lesion prior to randomization.
  • (ECOG) performance status of 0 or 1
  • Man or woman ≥ 18 years of age
  • Hematological function, as follows (≤ 10 days prior to randomization):

(ANC) ≥1.5 x 109/L count ≥ 100 x 109/L ≥ 9 g/dL - Renal function, as follows (≤ 10 days prior to randomization):

(CrCl) ≥ 50 mL/min calculated by the Cockcroft Gault method as follows:

Male creatinine clearance = (140 age) x (weight in Kg) / (serum Cr x 72) Female creatinine clearance = (140 age) x (weight in Kg) x 0.85 / (serum Cr x 72)

  • Hepatic function, as follows (≤ 10 days prior to randomization): (AST) ≤ 3 x (ULN) (≤ 5 x ULN if liver metastases) Alanine aminotransferase (ALT) ≤ 3 x ULN (≤ 5 x ULN if liver metastases) Total ≤ 1.5 x ULN
  • Electrolytes, as follows (≤ 10 days prior to randomization): Magnesium ≥ lower limit of normal (LLN)
  • Negative pregnancy test ≤ 72 hours prior to randomization (females of only)

Exclusion criteria

Exclusion Criteria:

  • Documented or symptomatic central nervous system
  • History of another primary cancer, except:

Curatively treated in situ cervical cancer, or Curatively resected non melanoma skin cancer, or Other primary solid tumor curatively treated with no known active disease present and no treatment administered for ≥ 2 years prior to randomization

  • Subjects whose only site of metastatic disease is a single spiculated lung nodule are assumed to have a second lung primary and are excluded unless there is unequivocal pathological confirmation of metastasis of the SCCHN primary
  • Nasopharyngeal carcinoma
  • Prior systemic treatment for metastatic and/or recurrent SCCHN Subjects with recurrent disease may have received re irradiation; however subjects who received chemotherapy concomitantly with re irradiation are excluded
  • Prior systemic chemotherapy for SCCHN as part of the initial multimodality treatment for locally advanced disease if completed \< 6 months prior to randomization
  • Prior cisplatin containing induction chemotherapy followed by cisplatin containing chemoradiotherapy
  • Prior anti EGFr antibody therapy (eg, cetuximab) or treatment with small molecule EGFr inhibitors (eg, gefitinib, erlotinib, lapatinib)
  • Subjects requiring agents (eg, methotrexate and cyclosporine), however are allowed
  • Known allergy or to any component of the study drugs
  • Major surgery requiring general anesthesia and a significant incision (ie, larger than what is required for placement of central venous access, percutaneous feeding tube, or ) ≤ 28 days or minor surgery (excluding central venous catheter placement, percutaneous feeding tube, and biopsy) ≤ 14 days prior to randomization. Subjects must have recovered from surgery related toxicities.
  • cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 1 year prior to randomization
  • History of interstitial lung disease eg, pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest computerized tomography (CT) scan
  • Symptomatic peripheral neuropathy grade ≥ 2 based on the (CTCAE) v3.0
  • Grade ≥ 3 hearing loss based on the CTCAE v3.0 Auditory/Ear (Hearing [without monitoring program])
  • Subjects not recovered from all previous acute radiotherapy related toxicities
  • Active infection requiring systemic treatment or any uncontrolled infection ≤ 14 days prior to randomization
  • Known positive test for (HIV) infection, virus, chronic infection (testing is not required in the absence of clinical suspicion)
  • Any co morbid condition that would increase risk of toxicity (eg, suspected or confirmed dihydropyrimidine deficiency)
  • Other procedures are excluded
  • Subject currently is enrolled in or ≤ 30 days since ending other investigational device or drug study(s), or subject is receiving other investigational agents(s)
  • Subject who is pregnant or breast feeding
  • Man or woman of child bearing potential not consenting to use adequate precautions ie, double barrier contraceptive methods (eg, diaphragm plus condom) during the course of the study and for 6 months after the last investigational product(s) administration for women, and 1 month for men
  • Subject unwilling or unable to comply with study requirements
  • Previously randomized into this study or Amgen study 20050251
  • Subject has any kind of disorder that compromises the ability of the subject to give written and/or to comply with study procedures
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Active comparator
    Panitumumab plus Chemotherapy

    Subjects receiving cisplatin and 5/FU and receiving Panitumumab who have with Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck

    Drug: Panitumumab

  • Active comparator
    Chemotherapy Alone

    Subjects receiving cisplatin and 5/FU and not receiving Panitumumab who have with Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck

    Drug: Cisplatin · Drug: 5FU

Interventions

  • This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone

  • This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone

  • Drug5FU

    This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC) of Total Plasma Cisplatin-derived Platinum Levels With and Without the Presence of Panitumumab

    AUC refers to area under the concentration curve from time 0 to last measurable concentration. AUC of total plasma cisplatin-derived platinum levels is estimated both for subjects receiving cisplatin with panitumumab and for subjects receiving cisplatin without panitumumab.

    Time frame: Levels measured at 0.5, 1, 2, 3, 4, 6 and 24 hours following start of cycle 2 cisplatin infusion

  2. Steady-state Plasma Concentrations (Css) for 5-FU With and Without the Presence of Panitumumab

    Steady-state plasma concentrations (Css) of 5-FU were estimated as the mean of two or more evaluable concentrations at 24, 72, and 96 hours after the start of 5-FU infusion. Css is estimated both for subjects receiving 5-FU with panitumumab and for subjects receiving 5-FU without panitumumab

    Time frame: 24 to 96 hours following start of cycle 2 infusion with 5-FU

07

Results

Posted Dec 13, 2013

Participant flow

Men and women ≥ 18 years of age with metastatic and/or recurrent squamous cell carcinoma of the head and neck were enrolled from 21 October 2008 to 23 August 2011. This study was conducted at 15 centers in Argentina, Brazil, France, Japan, Romania, and Russia.

Participant flow — Overall Study
MilestonePanitumumab Plus ChemotherapyChemotherapy Alone
Started3334
Completed1813
Not completed1521
Withdrew: Adverse event11
Withdrew: Withdrawal by subject68
Withdrew: Lost to follow-up01
Withdrew: Death54
Withdrew: Disease progression27
Withdrew: Ineligibility determined10

Outcome measures

PrimaryArea Under the Curve (AUC) of Total Plasma Cisplatin-derived Platinum Levels With and Without the Presence of Panitumumab

AUC refers to area under the concentration curve from time 0 to last measurable concentration. AUC of total plasma cisplatin-derived platinum levels is estimated both for subjects receiving cisplatin with panitumumab and for subjects receiving cisplatin without panitumumab.

Time frame:
Levels measured at 0.5, 1, 2, 3, 4, 6 and 24 hours following start of cycle 2 cisplatin infusion
Reported as:
Mean · ng*hr/mL
Area Under the Curve (AUC) of Total Plasma Cisplatin-derived Platinum Levels With and Without the Presence of Panitumumab
ng*hr/mLPanitumuab Plus ChemotherapyChemotherapy Alone
Area Under the Curve (AUC) of Total Plasma Cisplatin-derived Platinum Levels With and Without the Presence of Panitumumab58000 ± 953062300 ± 10200
PrimarySteady-state Plasma Concentrations (Css) for 5-FU With and Without the Presence of Panitumumab

Steady-state plasma concentrations (Css) of 5-FU were estimated as the mean of two or more evaluable concentrations at 24, 72, and 96 hours after the start of 5-FU infusion. Css is estimated both for subjects receiving 5-FU with panitumumab and for subjects receiving 5-FU without panitumumab

Time frame:
24 to 96 hours following start of cycle 2 infusion with 5-FU
Reported as:
Mean · ng/mL
Steady-state Plasma Concentrations (Css) for 5-FU With and Without the Presence of Panitumumab
ng/mLPanitumuab Plus ChemotherapyChemotherapy Alone
Steady-state Plasma Concentrations (Css) for 5-FU With and Without the Presence of Panitumumab328 ± 180378 ± 184

Adverse events

Collected over 54 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panitumumab Plus Chemotherapy—11/33 (33.3%)33/33 (100%)
Chemotherapy Alone—8/34 (23.5%)33/34 (97.1%)
Total—19/67 (28.4%)66/67 (98.5%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventPanitumumab Plus ChemotherapyChemotherapy AloneTotal
Cerebrovascular accidentNervous system disorders2/330/342/67
Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/332/342/67
NeutropeniaBlood and lymphatic system disorders1/330/341/67
ThrombocytopeniaBlood and lymphatic system disorders1/331/342/67
DysphagiaGastrointestinal disorders1/330/341/67
VomitingGastrointestinal disorders1/330/341/67
Performance status decreasedGeneral disorders1/330/341/67
PyrexiaGeneral disorders1/330/341/67
PneumoniaInfections and infestations1/330/341/67
Staphylococcal infectionInfections and infestations1/330/341/67
Most frequent other events
Showing 10 of 50
Most frequent other events
EventPanitumumab Plus ChemotherapyChemotherapy AloneTotal
NauseaGastrointestinal disorders17/3319/3436/67
AnaemiaBlood and lymphatic system disorders17/3316/3433/67
HypomagnesaemiaMetabolism and nutrition disorders17/3310/3427/67
NeutropeniaBlood and lymphatic system disorders16/3315/3431/67
RashSkin and subcutaneous tissue disorders15/330/3415/67
LeukopeniaBlood and lymphatic system disorders7/3312/3419/67
VomitingGastrointestinal disorders11/339/3420/67
AstheniaGeneral disorders11/336/3417/67
HypocalcaemiaMetabolism and nutrition disorders11/330/3411/67
Weight decreasedInvestigations10/3310/3420/67

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Panitumumab Plus ChemotherapyChemotherapy AloneTotal
Mean56.2 ± 7.558.3 ± 9.157.3 ± 8.4
Sex: Female, Male
Sex: Female, Male(Participants)Panitumumab Plus ChemotherapyChemotherapy AloneTotal
Female213
Male313364
08

Study locations

No study locations are listed for this record.

09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2008 to primary completion in Mar 2012, 41 months.

Results were first posted in Dec 2013, 1 year 8 months after primary completion.

Of 68 industry-sponsored phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's 41 months is close to that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2008
First posted
Sep 22, 2008
StartActual
Oct 21, 2008
Primary completionActual
Mar 30, 2012
CompletionActual
Mar 30, 2012
Results first posted
Dec 13, 2013
Last update
Nov 15, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00756444
Lead sponsor
Amgen
Collaborators
Takeda
Responsible party
Sponsor
First posted
Sep 22, 2008
Start date
Oct 21, 2008
Primary completion
Mar 30, 2012
Completion
Mar 30, 2012
Results posted
Dec 13, 2013
Last update
Nov 15, 2018

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Panitumumab · Cisplatin · Fluorouracil

Start the discussion